MAINTENANCE NOTIFICATION: There is a scheduled maintenance that will result in intermittent service interruption between 2pm and 5pm EST on Friday, April 3rd 2020
Menu
Search
Home > Courses > Clinical Management of Hepatitis C in Patients With and Without HIV Coinfection

Clinical Management of Hepatitis C in Patients With and Without HIV Coinfection

Clinical Management of Hepatitis C in Patients With and Without HIV Coinfection
Sorry, this learning module is not available for mobile devices.
This video is available at the Physicians Research Network website.

Original Release Date: 10/11/2011
Review Date: 6/29/2012
Presenter
  • Andrew Talal, MD, MPH
    Associate Medical Director
    Center for the Study of Hepatitis C at the Weill Cornell Medical College
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Understand the current approach to the diagnosis and staging of hepatitis C virus (HCV) infection.
  2. Know how HIV/HCV coinfection affects HCV pathogenesis.
  3. Appreciate treatment outcomes and side effect management to pegylated interferon and ribavirin in both HCV monoinfected and HIV/HCV coinfected individuals.
Presenter Bio
Andrew Talal, MD, MPH
Andrew Talal is Associate Professor of Medicine and Associate Medical Director at the Center for the Study of Hepatitis C at the Weill Cornell Medical College. Following his research fellowship in Gastrointestinal Epidemiology at the University of North Carolina at Chapel Hill, Dr Talal became a Rockefeller University Clinical Scholar in the laboratory of Dr. David Ho where he investigated the pathogenesis of HIV in the gut associated lymphoid tissue. In February 2000, Dr. Talal joined the faculty at Weill Cornell where he founded the Viral Hepatitis Clinic, the Center’s Translational Research Laboratory. His research interests include investigation of chemokines as mediators of fibrogenesis and noninvasive biomarkers of hepatic fibrosis. He also has been interested in HCV management in disenfranchised populations including HIV/HCV coinfected and those on opiate agonist therapy.
PRN Learning Modules